IP Library Granted Patent US 10,946,030
Granted Patent B2
US 10,946,030 · App. 15/663,356 · Granted Mar 16, 2021

Formulations of deoxycholic acid and salts thereof

Inventors: Robert Emil Hodge (McPherson, KS); Jeffrey Douglas Webster (Carmel, CA); Robert M. Moriarty (Michiana Shores, IN)
Assignee: Allergan Sales, LLC
A61K31/575A61K9/0019A61K47/02A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,946,030
App. No.
15/663,356
Granted
Mar 16, 2021
Kind
B2
Abstract

The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Claims (14)

1. A composition consisting essentially of about 0.4% w/v to less than 2% w/v of a salt of deoxycholic acid and a pharmaceutically acceptable excipient, wherein said composition, when dissolved in water, is maintained at a pH of about 8.1 to about 8.5 and, when so maintained, said composition does not form a precipitate.

2. The composition of claim 1 , wherein said excipient is a solvent, a buffer, a preservative, a lyophilization aid, or any combination thereof.

3. The composition of claim 2 , wherein said excipient is a solvent.

4. The composition of claim 3 , wherein said solvent is sterile water.

5. The composition of claim 2 , wherein said excipient is a preservative.

6. The composition of claim 5 , wherein said preservative is benzyl alcohol.

7. The composition of claim 6 , wherein said preservative is 0.9% benzyl alcohol.

8. The composition of claim 1 , wherein said composition has a pH of about 8.3.

9. The composition of claim 1 , wherein said salt is an alkali metal salt.

10. The composition of claim 9 , wherein said alkali metal salt is sodium.

11. The composition of claim 2 , wherein said excipient comprises a buffer.

12. The composition of claim 11 , wherein said buffer comprises a phosphate buffer.

13. The composition of claim 11 , wherein said buffer comprises 10 mM phosphate buffer.

14. The composition of claim 11 , wherein said buffer comprises dibasic sodium phosphate buffer.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Oct 10, 2019
From: KYTHERA BIOPHARMACEUTICALS, LLC; ALLERGAN SALES, LLC
To: ALLERGAN SALES, LLC
Reel/Frame 050680/0159 →
CHANGE OF NAME Recorded Oct 7, 2019
From: KYTHERA BIOPHARMACEUTICALS, INC.
To: KYTHERA BIOPHARMACEUTICALS, LLC
Reel/Frame 050648/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2018
From: HODGE, ROBERT EMIL; WEBSTER, JEFFREY DOUGLAS; MORIARTY, ROBERT M.
To: KYTHERA BIOPHARMACEUTICALS, INC.
Reel/Frame 047685/0371 →
Continuity (5)
Continuation 14091109 · Nov 26, 2013
Continuation 13207337 · Aug 10, 2011
Continuation In Part PCTUS2011031284 · Apr 5, 2011
Provisional Application 61483008 · May 5, 2011
Related Publication 20180015105A1 · Jan 18, 2018